ABL1

About

Location: 9q34.12

Mappings

HGNC: HGNC:76

Ensembl: ENSG00000097007

NCBI: 25

Refseq: NM_005157.6

View API

Biomarkers

ABL1 is involved in the following curated biomarkers.

Name Biomarker type Propositions Statements
BCR::ABL1 Gene fusion 17 50
ABL1 p.T315I Somatic variant 4 7

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
EMA (1) FDA (2) ABL1 p.T315I, BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
EMA (5) FDA (2) CD19 +, not BCR::ABL1 Acute Lymphoblastic Leukemia Blinatumomab
EMA (3) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Bosutinib
EMA (3) FDA (6) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (4) BCR::ABL1 Acute Lymphoblastic Leukemia Dasatinib
EMA (2) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (4) BCR::ABL1 Acute Lymphoblastic Leukemia Imatinib
EMA (3) FDA (6) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
EMA (1) FDA (2) BCR::ABL1 Acute Lymphoblastic Leukemia Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (2) ABL1 p.T315I, BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (2) FDA (2) ABL1 p.T315I, BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Ponatinib
EMA (2) CD22 +, not BCR::ABL1 Acute Lymphoblastic Leukemia Inotuzumab ozogamicin
EMA (2) not BCR::ABL1 Acute Lymphoblastic Leukemia Imatinib
EMA (1) not BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (1) ABL1 p.T315I, not BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (2) not BCR::ABL1 Acute Lymphoblastic Leukemia Dasatinib